189 filings
Page 6 of 10
8-K
bwfykq0
10 Nov 22
MindMed Reports Third Quarter 2022 Financial Results and Business Highlights
8:10am
8-K
exzgv
29 Sep 22
MindMed Announces Proposed Public Offering of Common Shares
4:29pm
424B5
zrclai n93h6k
29 Sep 22
Prospectus supplement for primary offering
4:26pm
424B5
sxj 3jxy8c
27 Sep 22
Prospectus supplement for primary offering
4:23pm
8-K
q2zok
14 Sep 22
MindMed Announces Compliance with Nasdaq Listing Requirements
8:01am
8-K
ksez26
26 Aug 22
MindMed Completes 1-for-15 Reverse Share Split
4:45pm
8-K
5aks2pp8in iv01h3g
11 Aug 22
MindMed Reports Second Quarter 2022 Financial Results and Business Highlights
4:03pm
8-K
un9duee0b
21 Jul 22
Regulation FD Disclosure
7:31am
8-K
digdhb 2hhjjt913aq4
30 Jun 22
MindMed Announces Completion of Share Redesignation
5:16pm
8-K
pd5g8gvzrk5r5p
2 Jun 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
jxw0 r09a
23 May 22
Departure of Directors or Certain Officers
4:32pm
EFFECT
btlametk
20 May 22
Notice of effectiveness
12:15am
8-K
u2ulz66kd
19 May 22
Regulation FD Disclosure
8:00am
10-Q
ss0jguk6f0c fy2fmaq
16 May 22
Quarterly report
8:21am
8-K
tiwv5p
16 May 22
MindMed Reports First Quarter 2022 Financial Results and Business Highlights
8:15am
DEFA14A
it7vr
13 May 22
Additional proxy soliciting materials
4:21pm
CORRESP
gf5hcf
12 May 22
Correspondence with SEC
12:00am
8-K
llf1fz9lrw pw8rr
11 May 22
MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
7:30am
UPLOAD
qs0j6ak1cp hesby
10 May 22
Letter from SEC
12:00am